Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

The decision to divest Opella is part of Sanofi’s ongoing strategy to become a pureplay biopharma company. Opella employs more than 11,000 people worldwide and is known for making Doliprane ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

2% stake in Opella, with Sanofi remaining a significant shareholder ... We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people ...

The sale of Sanofi's controlling stake in health business Opella is expected to close in ... but added that the company will still take a balanced approach to deals. Sanofi, one of the world's ...

2% stake in Opella, with Sanofi remaining ... approvals from the competent authorities. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles ...